Gefitinib CAS 184475-35-2 Purity >99.5% (HPLC)

Short Description:

Chemical Name: Gefitinib

Synonyms: Gefitinib Free Base; Iressa; ZD-1839

CAS: 184475-35-2

Purity: >99.5% (HPLC)

Appearance: White to Off-White Powder  

An EGFR-Tyrosine Kinase Inhibitor

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Gefitinib (CAS: 184475-35-2) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Gefitinib and intermediates, Please contact: alvin@ruifuchem.com

Gefitinib Intermediates:

Chemical Properties:

Chemical Name Gefitinib 
Synonyms Gefitinib Free Base; Iressa; ZD1839; ZD-1839; N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-Amine; N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-[3-(4-Morpholinyl)propoxy]-4-Quinazolinamine
Stock Status In Stock, Commercial Production  
CAS Number 184475-35-2
Molecular Formula C22H24ClFN4O3
Molecular Weight 446.91 g/mol
Melting Point 194.0 to 198.0℃ 
Density 1.322±0.06 g/cm3 
Water Solubility  Insoluble in Water 
Solubility  Soluble in DMSO 
Storage Temp.  Room Temperature  
Shipping Ambient  
COA & MSDS Available
Origin Shanghai, China
Brand Ruifu Chemical

Specifications:

Items Inspection Standards Results
Appearance White to Off-White Powder  Complies      
Loss on Drying <0.50% 0.13% 
Residue on Ignition <0.20% 0.06% 
Single Impurity   <0.10% 0.09%
Total Impurities <0.50% 0.20%
Heavy Metals (Pb) ≤10ppm <10ppm 
Purity / Analysis Method >99.5% (HPLC)  99.80% 
Infrared Spectrum Consistent with Structure Complies 
1H NMR Spectrum Consistent with Structure Complies
Conclusion The product has been tested and complies with the given specifications

Package/Storage/Shipping:

Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery. 

Note:

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
None of the products will be supplied to countries in which this could be in conflict with the existing patents. However the final responsibility lies with the Buyer. 

Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock    

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality AssuranceStrict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
SamplesMost products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory AuditFactory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
TransportationBy Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom SynthesisCan provide custom synthesis services to best fit your research needs.
Payment TermsProforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc. 

63-91-2 - Safety Information:

Safety Description 24/25 - Avoid contact with skin and eyes.
HS Code 2934999099

184475-35-2 - Application:

Gefitinib (CAS: 184475-35-2) is a highly specific anti-tumor targeted therapeutic drug developed by AstraZeneca, UK. It is the first molecular targeted drug for the treatment of non-small cell lung cancer. It works by selectively inhibiting the signal transduction pathway of epidermal growth factor receptor tyrosine kinase (EGFR-TK). Epidermal growth factor (EGF) is a polypeptide with a relative molecular mass of 6.45 × 103, which can combine with epidermal growth factor receptor (EGFR) on the target cell membrane to produce biological effects. EGFR is a tyrosine kinase (TK) type receptor. When it binds to EGF, it can promote TK activation in the recipient body, resulting in autophosphorylation of receptor tyrosine residues, providing continuous division signals to cells, causing cell proliferation and differentiation. EGFR is abundant in human tissues and is highly expressed in malignant tumors. By blocking the EGFR signaling pathway on the cell surface, gefitinib hinders tumor growth, metastasis and angiogenesis, and can induce apoptosis of tumor cells. In August 2002, gefitinib was first marketed in Japan as a first-line treatment for non-small cell lung cancer under the trade name Iressa. In May 2003, the U.S. Food and Drug Administration approved gefitinib as the third-line monotherapy for patients with advanced non-small cell lung cancer who were ineffective with platinum-based anticancer drugs and docetaxel chemotherapy. At present, it has been approved by Australia, Japan, Argentina, Singapore and South Korea for the treatment of advanced non-small cell lung cancer. On February 28, 2005, the China Food and Drug Administration approved gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that had previously received chemotherapy. It is not currently approved for use as first-line therapy for advanced NSCLC. On July 1, 2009, the European Medicines Agency officially approved gefitinib for the first-line, second-line and third-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR gene mutations in adults.

  • Write your message here and send it to us